Shan Feng of Tsinghua University in China will develop a novel reagent called DCAF to eliminate antibody-dependence-enhanced (ADE) Dengue virus infection. DCAF stands for Dual-functional Conjugate of Antigenic peptide and Fc-III tag, which is designed for the blocking of cross-reactive antibodies that can enhance secondary infection of Dengue virus. In the current phase, they will synthesize a group of DCAF molecules to test their binding affinities with the antibodies of Dengue virus 2 and to evaluate whether these molecules can be used to block the ADE process.
Grant ID
TSING012
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False